ASPIRE Publications

Jared Baeten
ASPIRE Protocol Chair
Goals for ASPIRE publications

- Collaboration
- High quality manuscripts
- Timely reporting and wide dissemination
- Capacity building of young investigators
- Compliance with ethics and with authorship integrity
Making the goals a reality

- Ensure MTN-020 data are cleaned, analyzed, and completed for publication as soon as possible;
- Publications utilizing MTN-020 data are written and revised in a timely fashion;
- All team members are provided an opportunity to develop and participate in the development of MTN-020 manuscripts.
ASPIRE Publications Policy

• The ASPIRE Publications Policy follows guidance set out in Section 5 of the MTN MOP

• The policy is in draft form and under review by site investigators and ASPIRE management team

• Final version to be disseminated after the annual meeting
Big Picture

• All concepts must first be approved by the MTN-020 Publications Committee. Site-level concepts and abstracts should be approved by the IoR first.
• Lead author will manage ASPIRE Pubs Com and MTN MRC approvals and track all timelines
• FHI 360 will manage sponsor (IPM) approvals
• It is the lead author’s responsibility to provide FHI 360 and the MTN MRC will all final versions (oral presentation, poster, or manuscript)
Authorship Guidelines

- ICMJE:
  - Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
  - Drafting the work or revising it critically for important intellectual content; AND
  - Final approval of the version to be published; AND
  - Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Authorship

• Our approach:
  – The Pubs Com will help assign writing teams for each ASPIRE manuscript
  – Authorship suggestions from the Pubs Com will be based on interest expressed (based on discussions or similar concepts submitted by other individuals), involvement in the topic area, or role/responsibilities in ASPIRE
  – ICMJE criteria will be used.
Timelines

• As we all know, when the trial has been we have not analyzed post-randomization data.

• We have completed the baseline manuscript (submitted!) and the first publication will be the primary efficacy and safety manuscript (late 2015 submission...!). Thereafter, we will move through a priority list.
Manuscript Priorities and Development

- Solicit concepts from protocol team (June/July 2015)
- Publications meeting in Cape Town (Oct 2015)
- Regular publication calls with PC, IoRs, and lead authors
Manuscript Expectations

- Priorities and manuscripts in development will be reviewed on periodic publications calls.
- Once analysis is underway, forward progress is expected on manuscript development. If progress is not made, the Pubs Comm could assign a new lead author to the manuscript.